Special Issue on "Cdk5 and Brain Disorders": Prologue

Overview

Journal Brain Disord Ther

Publisher Omics Publishing Group

Date 2017 Jan 10

PMID 28066692

Authors

Jyotshnabala Kanungo

Affiliations

Soon will be listed here.

Abstract

Cyclin-dependent kinase 5 (Cdk5) was identified almost two decades ago as a Tau kinase specific to the nervous system. Shortly after its discovery, it was revealed that this atypical member of the CDK family does not partner with cyclins but with two other proteins, p35 and p39. P35 is predominantly expressed in post-mitotic neurons, whereas p39 is expressed in many different tissues including the brain, pancreas, muscle cells, neutrophils, and many other cell types. A proline-directed serine/threonine (S/T) kinase, predominantly active in the nervous system, Cdk5 regulates a multitude of functions including nervous system development, neuronal migration, cytoskeletal dynamics, axonal guidance, synaptic plasticity, neurotransmission, neuronal survival and death, to mention a few. In association with its ubiquitous expression in other tissues, Cdk5 is implicated in a wide range of functions, such as gene transcription, vesicular transport, apoptosis, cell adhesion, migration, exocytosis, etc. A focal point of investigation surrounding Cdk5 is its deregulation in pathogenic processes of neurodegenerative disorders, which has emphasized on its hyperactivation by p25, a calpain-cleaved product of p35 leading to Tau and neurofilament hyperphosphorylation followed by neuronal death. What has intrigued researchers about Cdk5 is its tight regulation in carrying out many normal physiological functions while its deregulation under pathological conditions, is linked to neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Neiman Pick's Type C disease and others. Between these two so-called 'good Cdk5 (Cdk5/p35)' and 'bad Cdk5 (Cdk5/p25)', the latter has become the target for therapeutic intervention in neurodegenerative disorders.

References

Iijima K, Ando K, Takeda S, Satoh Y, Seki T, Itohara S . Neuron-specific phosphorylation of Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. J Neurochem. 2000; 75(3):1085-91. DOI: 10.1046/j.1471-4159.2000.0751085.x. View

Van den Haute C, Spittaels K, Van Dorpe J, Lasrado R, Vandezande K, Laenen I . Coexpression of human cdk5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice. Neurobiol Dis. 2001; 8(1):32-44. DOI: 10.1006/nbdi.2000.0333. View

Hashiguchi M, Saito T, Hisanaga S, Hashiguchi T . Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J Biol Chem. 2002; 277(46):44525-30. DOI: 10.1074/jbc.M207426200. View

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

Cruz J, Tseng H, Goldman J, Shih H, Tsai L . Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron. 2003; 40(3):471-83. DOI: 10.1016/s0896-6273(03)00627-5. View

Alvarez A, Toro R, Caceres A, Maccioni R . Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett. 1999; 459(3):421-6. DOI: 10.1016/s0014-5793(99)01279-x. View

Hallows J, Iosif R, Biasell R, Vincent I . p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease. J Neurosci. 2006; 26(10):2738-44. PMC: 6675168. DOI: 10.1523/JNEUROSCI.4834-05.2006. View

Shetty K, Link W, Pant H . cdc2-like kinase from rat spinal cord specifically phosphorylates KSPXK motifs in neurofilament proteins: isolation and characterization. Proc Natl Acad Sci U S A. 1993; 90(14):6844-8. PMC: 47029. DOI: 10.1073/pnas.90.14.6844. View

Hallows J, Chen K, DePinho R, Vincent I . Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice. J Neurosci. 2003; 23(33):10633-44. PMC: 6740918. View

10.

Sato H, Nishimoto I, Matsuoka M . ik3-2, a relative to ik3-1/cables, is associated with cdk3, cdk5, and c-abl. Biochim Biophys Acta. 2002; 1574(2):157-63. DOI: 10.1016/s0167-4781(01)00367-0. View

11.

Wei F, Tomizawa K . Cyclin-dependent kinase 5 (Cdk5): a potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus. Mini Rev Med Chem. 2007; 7(10):1070-4. DOI: 10.2174/138955707782110114. View

12.

Tsai L, Lee M, Cruz J . Cdk5, a therapeutic target for Alzheimer's disease?. Biochim Biophys Acta. 2004; 1697(1-2):137-42. DOI: 10.1016/j.bbapap.2003.11.019. View

13.

Lopez-Tobon A, Castro-Alvarez J, Piedrahita D, Boudreau R, Gallego-Gomez J, Cardona-Gomez G . Silencing of CDK5 as potential therapy for Alzheimer's disease. Rev Neurosci. 2011; 22(2):143-52. DOI: 10.1515/RNS.2011.015. View

14.

Patrick G, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai L . Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999; 402(6762):615-22. DOI: 10.1038/45159. View

15.

Otth C, Concha I, Arendt T, Stieler J, Schliebs R, Gonzalez-Billault C . AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis. 2002; 4(5):417-30. DOI: 10.3233/jad-2002-4508. View

16.

Zheng Y, Amin N, Hu Y, Rudrabhatla P, Shukla V, Kanungo J . A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J Biol Chem. 2010; 285(44):34202-12. PMC: 2962518. DOI: 10.1074/jbc.M110.134643. View

17.

Fischer A, Sananbenesi F, Pang P, Lu B, Tsai L . Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron. 2005; 48(5):825-38. DOI: 10.1016/j.neuron.2005.10.033. View

18.

Zheng Y, Li B, Amin N, Albers W, Pant H . A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells. Eur J Biochem. 2002; 269(18):4427-34. DOI: 10.1046/j.1432-1033.2002.03133.x. View

19.

Fischer A, Sananbenesi F, Spiess J, Radulovic J . Cdk5: a novel role in learning and memory. Neurosignals. 2003; 12(4-5):200-8. DOI: 10.1159/000074621. View

20.

Chae T, Kwon Y, Bronson R, Dikkes P, Li E, Tsai L . Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron. 1997; 18(1):29-42. DOI: 10.1016/s0896-6273(01)80044-1. View